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Platinum drugs continue to be one of the most 
effective and prescribed families of agents used 
in the treatment of human cancers [1]. While 
there is a continued interest in improving the use 
of approved drugs for different cancer types and 
in different drug combinations, the development 
of new, small molecule platinum drugs is out of 
favor with drug companies. This feeling is not 
isolated to platinums, but to all cytotoxics, and 
the long development times of satraplatin and 
picoplatin (Pionard, WA, USA) and the failure 
of BBR3464 have only made this worse. There is 
now a clear focus internationally on the develop-
ment of targeted therapeutics for cancer, based 
on the rapidly increasing knowledge of cancer 
biology and the identification of target able and 
drugable cancer proteins [2]. As such, I believe if 
there is to be a future for platinum drug develop-
ment then one potential lies in improving the 
delivery and effectiveness of the already approved 
platinum drugs: cisplatin, oxaliplatin, heptapla-
tin and lobaplatin. The focus of this editorial is 
on the nanoparticle-based delivery of platinum 
drugs, and whilst this seems the logical next 
step in platinum development, their commer-
cialization may not be as straight forward as it 
would be for small molecule platinum drugs, 
and potentially more risky.
Types of nanoparticles
A number of different nanoparticle-based plati-
nums have been examined in the past, all with 
unique advantages over normal small-molecule 
platinum drugs. Liposomes and micelles have 
been of interest in drug delivery for a number of 
decades and the success of the liposomal formu-
lation of doxorubicin, Doxil® (Janssen Products, 
LP, NJ, USA) is a testament to the viability of 
nanotechnology in this field. Currently, a lipo-
somal formulation of cisplatin is in clinical tri-
als, Lipoplatin™ (Regulon, Athens, Greece) [3], 
and a polymer formulation of oxaliplatin is 
also under development, ProLindac™ (Access 
Pharmaceuticals, TX, USA) [4]. Recently a 
micelle formulation of oxaliplatin, Aroplatin™ 
(Aronex Pharmaceuticals, TX, USA), was with-
drawn from commercial development [1]. Closer 
to the discovery end of the drug development 
pipeline, other types of nanoparticles are being 
examined, including: carbon nanotubes and 
nanohorns [5,6], mineral and metallic nano-
particles (silica, gold and gold-coated iron oxide) 
[7–9] and dendrimers [10,11].
Benefits of nanoparticles to 
platinum drugs
Nanoparticles are used to improve the delivery 
of platinum drugs principally through passive 
targeting of solid tumors via the enhanced 
perm eability and retention (EPR) effect [12]. 
The passive targeting of tumors occurs because 
the vasculature surrounding tumors is highly 
porous, whereas the vasculature of normal tissue 
tends to be smooth and well aligned. As such, 
nanoparticles can get trapped in the tumor vas-
culature, thus leading to a greater concentration 
of drug in these areas. There is no perfect size 
for nanoparticles to take advantage of the EPR 
effect, although the consensus seems to be a 
particle size smaller than 100 nm is more ideal.
Using nanoparticles for platinum drug deliv-
ery also has several other benefits. The large sur-
face areas of nanoparticles facilitate the attach-
ment of a large number of drug molecules. 
Recent research has shown that up to 70,000 cis-
platin-like drug molecules can be attached to the 
surface of a single gold nanoparticle [13]. Second, 
while platinum drugs are usually taken up by 
cells via passive diffusion, copper transporters or 
organic cation transporters, the use of nanopar-
ticles can facilitate uptake via endocytosis. The 
large surface area of nanoparticles also allows the part of
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simultaneous attachment of a large number of 
tumor-targeting groups to the drugs (e.g., aptam-
ers [14], antibodies [15] and substrates like folate 
[16]), thus further improving tumor selectivity 
and improving cellular uptake through receptor-
mediated endocytosis. Third, nanoparticles can 
be used to facilitate controlled platinum drug 
release. For example, platinum drugs can be teth-
ered to nanoparticles through carboxylate func-
tional groups. In the bloodstream where the pH 
is near 7, the platinum drugs remain attached. 
Upon uptake into the acidic environment of a 
cancer cell (pH 5–6), the carboxylate groups 
become protonated, thus releasing the drug. 
Alternatively, the platinum drugs can be in the 
platinum (IV) oxidation state and when reduced 
in vivo, yield the corre sponding platinum (II) 
complex, free of the nanoparticle [17].
Problems with nanoparticles
Of all the benefits that nanoparticles can provide 
in improving the delivery of platinum anti cancer 
drugs, they are not without their problems, most 
of which are not an issue for small-molecule 
drugs. Some of these problems may be enough 
to dissuade interest from companies to under-
take their development, the problems may not 
have solutions, or may have solutions that are 
not acceptable for drug approval authorities and 
society.
The first issue has to do with accurate drug 
dosing. A drug is only effective when a predict-
able, and correct, dose is delivered to patients. 
There are two factors that can affect accurate 
drug dosing of nanoparticle-based platinum 
drugs. Whilst nanoparticles can be tethered with 
large numbers of drug molecules, the batch-to-
batch variability can be as high as 30% and the 
variability increases with the increasing num-
ber of attached drug molecules. This may stem 
from the reproducibility and variability in nano-
particle size from batch to batch, as is observed 
for metallic spheres and carbon nanotubes. 
Further to this, those nanoparticle systems that 
are polymer- or dendrimer-based may contain 
amine groups to which platinum drugs can irre-
versibly bind (i.e., polyamidoamine dendrimers) 
[10]. The extent of the irreversible binding can 
be time dependent, and unpredictable, affect-
ing both the delivered dose and making storage 
more difficult.
Second, some nanoparticles can only be syn-
thesized at very low concentrations. For exam-
ple, gold nanoparticles made using either the 
Turkehich–Frens or the Brust–Schiffrin meth-
ods are only stable at nanomolar concentrations. 
Scale up at higher concentrations can lead to 
nanoparticle agglomeration and precipitation. 
This is less of an issue for dendrimers that are 
stable at millimolar concentrations. Metallic 
nanoparticles may also change size/shape during 
manufacture and in storage [13].
Third, the safety of nanoparticles in general is 
not well understood. Whilst gold nanoparticles 
are generally regarded as safe, mineral nano-
particles and carbon nanotubes are thought to 
cause diseases such as mesothelioma and protein 
citrullination (a major cause of arthritis) [18,19].
“Of all the benefits that nanoparticles can 
provide in improving the delivery of platinum 
anticancer drugs, they are not without their 
problems, most of which are not an issue for 
small-molecule drugs.”
Finally, the screening and selection of a 
lead nanoparticle-based drug appears to be 
more complex than for small molecule testing. 
Because nanoparticles are used to target solid 
tumors, replicating the EPR in vitro is very dif-
ficult and in normal growth inhibition assays, 
no difference in cytotoxicity may be observed 
between the nanoparticle-based drug and con-
trol drugs. As such, a greater number and ear-
lier in vivo experiments may be required, thus 
greatly adding to the cost of the research, both 
financially and in terms of the expertise required 
by research team members. In addition, there 
is a conscientious push to reduce the number 
of animals used in drug testing, and thus, the 
development of nanoparticle-based drugs may 
have further ethical and wider societal issues.
Future of nanoparticle-based 
platinum drugs
There are obvious benefits to the development 
of nanoparticle-based platinum drugs, includ-
ing better selectivity and less severe side effects, 
but these new systems will need to provide sig-
nificantly improved effectiveness to overcome 
the current reluctance by most pharmaceuti-
cal companies to develop cytotoxics. I feel that 
the litmus test will be the success or failure 
of Lipoplatin and ProLindac, and only once 
these have gained market approval will compa-
nies become less risk averse to platinums. The 
opportunity cost that arises from a global focus 
on pursuing nano particle-based platinums will 
be at the expense of other avenues for research, 
such as platinum drugs that derive their activity 
not through DNA binding, but as ‘molecularly 
targeted drugs’ for cancer-specific proteins and 
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enzymes, similar to the small molecule organic 
and antibody-based drugs currently being 
investigated.
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